Edgewise Therapeutics (NASDAQ:EWTX) completed the sale of sevasemten and its muscular dystrophy business to Servier for $1.55 billion in upfront cash and up to $1.1 billion in potential regulatory and commercial milestones.
Clearmind Medicine (NASDAQ:CMND) shared early insights from its ongoing Phase I/IIa trial of CMND-100, an investigational MEAI-based compound being evaluated for alcohol use disorder, following a June 10 webinar with study investigators from Yale and Johns Hopkins.
SLB (NYSE:SLB) announced that its OneSubsea joint venture was awarded a major engineering, procurement and construction contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire, covering subsea production systems for 13 wells.
Third Coast Bancshares (NYSE:TCBX) completed the sale of substantially all assets of its subsidiary Third Coast Commercial Capital to Gulf Coast Bank & Trust for approximately $27.5 million, generating a $3.5 million gain.
Aethlon Medical (NASDAQ:AEMD) reported that patients in the second cohort of its oncology feasibility study exhibited biological changes.
Diana Shipping (NYSE:DSX) extended its tender offer to acquire all outstanding shares of Genco Shipping & Trading (NYSE:GNK) it does not already own through July 24, 2026, after shareholders tendered 11.08 million shares.
Greenfire Resources (NYSE:GFR) agreed to acquire private thermal oil sands producer Connacher Oil and Gas for an estimated C$1.277 billion in cash, net of expected closing adjustments, expanding its production base and reserves position.
The Metals Royalty Company (NASDAQ:TMC) reported that its Mesabi Metallics iron ore royalty project in Nashwauk, Minnesota completed its first production blast on July 10, 2026, marking a step toward planned pellet production.
The Ethereum Foundation's Protocol Security team identified and patched a significant security vulnerability in the network's core software after deploying coordinated artificial intelligence agents to analyse the codebase.
Ocugen (NASDAQ:OCGN) signed a binding term sheet with Roots Pharmaceutical and strategic partner Al-Dhow International Holding to negotiate an exclusive license for OCU400, its investigational modifier gene therapy for retinitis pigmentosa, across the Middle East and North Africa region.
GARANTA JÁ SEU GRAFA EDGE
Sign up free to unlock this feature
Vamos ativar um teste de 30 dias do Edge como presente de boas-vindas
